What is the evidence grade for Chonluten?

Chonluten carries an evidence grade of Preliminary (score 2.3). Animal or in-vitro only

What is the risk band for Chonluten?

Chonluten is rated Moderate risk. Known AEs, monitoring advised

What is the regulatory status of Chonluten?

Chonluten has a status of Investigational based on Peptides Pub's classification of clinical stage and approval data.

What research goals is Chonluten studied for?

Chonluten is studied in relation to the following research goals: Tissue recovery.

PEP-0020Investigational

Chonluten

Also known as

Short tripeptide studied for lung and respiratory tissue recovery. Preliminary evidence — investigational stage; available data are preclinical or limited small-cohort studies.

Evidence

Preliminary· 2.3

Animal or in-vitro only

Risk band

Moderate

Known AEs, monitoring advised

Research goals

Tissue recovery

Summary

Chonluten is a short Khavinson-type peptide, and the available evidence is limited to a single in-vitro study rather than any human trial. In that study, Khavinson peptides inhibited LPS-stimulated expression of TNF and the pro-inflammatory cytokine IL-6 in terminally differentiated THP-1 monocyte/macrophage cells and reduced cell adhesion to activated endothelial cells, suggesting anti-inflammatory and TNF-tolerance-inducing activity in cell culture ^[1]. There are no randomized controlled trials, meta-analyses, or human interventional studies of administering Chonluten as a therapeutic, so any clinical benefit is entirely unproven and the evidence is preliminary and laboratory-only.

Sources

1. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line International journal of molecular sciences, 2022.

For educational purposes only.

← Back to the encyclopedia